Mylan ‘Likely To Win’ On US Tecfidera Challenge
Verdict In Litigation Is Expected By 20 June
Mylan was shot down in February this year by the USPTO after challenging Biogen’s key US patent 8,399,514 protecting Tecfidera. However, the ANDA sponsor has been backed by Bernstein to prevail in separate district court proceedings, clearing a path to potential market entry years earlier than otherwise anticipated.
